Article
Cell Biology
Yuanzhou Zhang, Shunshun Liang, Bowen Xiao, Jingying Hu, Yechun Pang, Yuling Liu, Juan Yang, Junpin Ao, Lin Wei, Xiaoying Luo
Summary: This study shows that ErbB3/EGFR receptor tyrosine kinase activity is increased in colorectal cancer cells, and miR-323a-3p can directly target both ErbB3 and EGFR, promoting apoptosis in CRC cells. Furthermore, miR-323a-3p acts as a multi-ErbBs inhibitor, enhancing sensitivity to gefitinib and preventing acquired resistance.
CELL DEATH & DISEASE
(2022)
Review
Immunology
Balakarthikeyan Janani, Mayakrishnan Vijayakumar, Kannappan Priya, Jin Hee Kim, D. S. Prabakaran, Mohammad Shahid, Sameer Al-Ghamdi, Mohammed Alsaidan, Nasraddin Othman Bahakim, Mohammad Hassan Abdelzaher, Thiyagarajan Ramesh
Summary: Colorectal carcinoma is a common and lethal form of cancer, with a high rate of metastasis. Targeted nanotherapy, particularly targeting EGFR, has the potential to improve surgical control and reduce tumor-related mortality. Antibodies conjugated with drug-loaded carriers can increase drug effectiveness and quantity delivered to the target site.
Article
Biochemistry & Molecular Biology
Ye-Lim Park, Hwang-Phill Kim, Chan-Young Ock, Dong-Wook Min, Jun Kyu Kang, Yoo Joo Lim, Sang-Hyun Song, Sae-Won Han, Tae-You Kim
Summary: The emergence of RAS/RAF mutant clone is the main feature of EGFR inhibitor resistance in KRAS wild-type colon cancer. In this study, researchers successfully isolated cetuximab-resistant (CR) clonality cells from an in vitro system and found that these cells showed a higher EMT signature and increased expression of CXCL1/5. The study also revealed that CXCL1/5 expression in CR cells was regulated by SNAI2/NFKB and transactivated EGFR through CXCR/MMPI/EGF axis via autocrine signaling.
Review
Oncology
Gunnar Folprecht, Erika Martinelli, Thibault Mazard, Dominik P. Modest, Akihito Tsuji, Regina Esser, Chiara Cremolini, Alfredo Falcone
Summary: Triplet chemotherapy regimens in combination with anti-EGFR agents or bevacizumab are recommended standard treatments for unresectable mCRC. While the dosing schedule of FOLFOXIRI with bevacizumab is established, the optimal dosing with anti-EGFR agents is still unknown. Clinical trials have shown improved survival and response rates with FOLFOXIRI, alone or combined with bevacizumab, for mCRC patients, and promising results with anti-EGFR agents.
CANCER TREATMENT REVIEWS
(2022)
Review
Oncology
Yong Li, Xian Chen, Wenzhu Li, Yongsong Ye, Xiaohua Du, Shaodan Sun, Lirong Liu, Haibo Zhang
Summary: This study reported a successful case of treating mCRC patient with cetuximab in combination with fruquintinib after resistance to chemotherapy, showing good response. The mechanisms of this combination therapy and other clinical research on combined treatments were discussed, highlighting the potential benefits of combining small-molecule anti-vascular drugs with anti-EGFR in CRC treatment.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Qian Wu, Huan Wang, Suqin Zhang, Yifei Zeng, Wei Yang, Wenjun Pan, Guodai Hong, Wenbin Gao
Summary: This meta-analysis evaluated the efficacy and safety of triplet chemotherapy plus anti-EGFR target agents in potentially resectable metastatic colorectal cancer (mCRC) patients. The results showed that this treatment increased the objective response rate and the resection rate of colorectal liver metastasis. Adverse events were manageable. Further high-quality randomized controlled trials are needed for validation.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Cell Biology
Hong Lu, Hao Zhang, Mei-lin Weng, Jin Zhang, Nan Jiang, Juan P. Cata, Duan Ma, Wan-Kun Chen, Chang-Hong Miao
Summary: Morphine treatment can activate MOR and promote proliferation, migration, and invasion in CRC cells, as well as increase resistance to cetuximab. It induces EGFR transactivation, leading to protumoral effects in CRC cell lines.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Article
Oncology
Lu Yang, Arup Bhattacharya, Yun Li, Sandra Sexton, Xiang Ling, Fengzhi Li, Yuesheng Zhang
Summary: Resistance to EGFR inhibitors in colorectal cancer is primarily due to the inability of the inhibitors to downregulate their target. The combination treatment with PEPDG278D overcomes this resistance.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Giovanni Randon, Rona Yaeger, Jaclyn F. Hechtman, Paolo Manca, Giovanni Fuca, Henry Walch, Jeeyun Lee, Elena Elez, Jenny Seligmann, Benedetta Mussolin, Filippo Pagani, Marco Maria Germani, Margherita Ambrosini, Daniele Rossini, Margherita Ratti, Francesc Salva, Susan D. Richman, Henry Wood, Gouri Nanjangud, Annunziata Gloghini, Massimo Milione, Alberto Bardelli, Filippo de Braud, Federica Morano, Chiara Cremolini, Filippo Pietrantonio
Summary: EGFR amplification is significantly associated with left primary tumor sidedness and RAS/BRAF wild-type status. EGFR-amplified tumors are usually MSS and HER2 nonamplified, with a higher median fraction of genome altered. Patients with EGFR amplification tend to have longer overall survival and better outcomes when exposed to anti-EGFR-based therapy.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Article
Gastroenterology & Hepatology
Maochao Luo, Zhao Huang, Xingyue Yang, Yan Chen, Jingwen Jiang, Lu Zhang, Li Zhou, Siyuan Qin, Ping Jin, Shuyue Fu, Liyuan Peng, Bowen Li, Yongting Fang, Wenchen Pu, Yanqiu Gong, Yu Liu, Zhixiang Ren, Qiu-Luo Liu, Cun Wang, Fangqiong Xiao, Du He, Hongying Zhang, Changlong Li, Heng Xu, Lunzhi Dai, Yong Peng, Zong-Gung Zhou, Canhua Huang, Hai-Ning Chen
Summary: This study identifies PHLDB2 as a key player in latent liver metastasis of colorectal cancer (CRC). Chemotherapeutic-induced oxidative stress promotes N6-methyladenosine modification of PHLDB2 messenger RNA, leading to increased protein expression of PHLDB2. Upregulated PHLDB2 stabilizes EGFR and promotes its nuclear translocation, resulting in activation of EGFR signaling and resistance to cetuximab. The study proposes PHLDB2 as a potential target for CRC treatment.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Elena Elez, Javier Ros, Jose Fernandez, Guillermo Villacampa, Ana Belen Moreno-Cardenas, Carlota Arenillas, Kinga Bernatowicz, Raquel Comas, Shanshan Li, David Philip Kodack, Roberta Fasani, Ariadna Garcia, Javier Gonzalo-Ruiz, Alejandro Piris-Gimenez, Paolo Nuciforo, Grainne Kerr, Rossana Intini, Aldo Montagna, Marco Maria Germani, Giovanni Randon, Ana Vivancos, Ron Smits, Diana Graus, Raquel Perez-Lopez, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio, Rodrigo Dienstmann, Josep Tabernero, Rodrigo A. Toledo
Summary: In colorectal cancer patients, inactivating mutations in the RNF43 gene are associated with patients' response rates and survival outcomes to anti-BRAF/EGFR therapy. This suggests that the status of the RNF43 gene may serve as a predictive biomarker for patients' clinical outcomes.
Article
Oncology
Kun-Han Lee, Wei-Shone Chen, Jeng-Kai Jiang, Shung-Haur Yang, Huann-Sheng Wang, Shih-Ching Chang, Yuan-Tzu Lan, Chun-Chi Lin, Hung-Hsin Lin, Sheng-Chieh Huang, Hou-Hsuan Cheng, Yee Chao, Hao-Wei Teng
Summary: Metastatic middle/low rectal cancer shows lower efficacy in anti-EGFR treatment compared to left-sided colon cancer, both in terms of progression-free survival, overall survival, and overall response rates for both first-line and non-first-line treatment. TCGA analysis reveals genetic heterogeneity in rectal tumors, showing shared features with both left- and right-sided colon cancer.
BRITISH JOURNAL OF CANCER
(2021)
Article
Biochemistry & Molecular Biology
Joris van de Haar, Xuhui Ma, Salo N. Ooft, Pim W. van der Helm, Louisa R. Hoes, Sara Mainardi, David J. Pinato, Kristi Sun, Lisa Salvatore, Giampaolo Tortora, Ina Valeria Zurlo, Silvana Leo, Riccardo Giampieri, Rossana Berardi, Fabio Gelsomino, Valeria Merz, Federica Mazzuca, Lorenzo Antonuzzo, Gerardo Rosati, Chara Stavraka, Paul Ross, Maria Grazia Rodriquenz, Michele Pavarana, Carlo Messina, Timothy Iveson, Federica Zoratto, Anne Thomas, Elisabetta Fenocchio, Margherita Ratti, Ilaria Depetris, Massimiliano Cergnul, Cristina Morelli, Michela Libertini, Alessandro Parisi, Michele De Tursi, Nicoletta Zanaletti, Ornella Garrone, Janet Graham, Raffaella Longarini, Stefania Maria Gobba, Angelica Petrillo, Emiliano Tamburini, Nicla La Verde, Fausto Petrelli, Vincenzo Ricci, Lodewyk F. A. Wessels, Michele Ghidini, Alessio Cortellini, Emile E. Voest, Nicola Valeri
Summary: Genomic analysis identified KRAS(G12) mutations as potential biomarkers of resistance to trifluridine/tipiracil treatment in metastatic colorectal cancer. Real-world data and phase 3 clinical trial data confirmed the significant association between KRAS(G12) mutations and reduced overall survival. These findings provide important implications for precision medicine in approximately 28% of patients with metastatic colorectal cancer.
Review
Medicine, General & Internal
Gerardo Rosati, Michele Montrone, Carmen Pacilio, Alfredo Colombo, Giuseppe Cicero, Fernando Paragliola, Angelo Vaia, Luigi Annunziata, Domenico Bilancia
Summary: Although colorectal cancer is increasingly diagnosed in older patients, their representation in clinical trials is insufficient, leading to unclear treatment guidelines. Targeted therapy for elderly patients with wild-type RAS and BRAF is challenging due to potential toxicity. Comprehensive geriatric assessment and recent studies provide important data for differentiating treatment outcomes based on functional status.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
David Sefrioui, Ludivine Beaussire, Andre Gillibert, France Blanchard, Emmanuel Toure, Celine Bazille, Anne Perdrix, Frederic Ziegler, Alice Gangloff, Melanie Hassine, Caroline Elie, Anne-Laure Bignon, Aurelie Parzy, Philippe Gomez, Caroline Thill, Florian Clatot, Jean-Christophe Sabourin, Thierry Frebourg, Jacques Benichou, Karine Bouhier-Leporrier, Marie-Pierre Gallais, Nasrin Sarafan-Vasseur, Pierre Michel, Frederic Di Fiore
Summary: The study confirmed the importance of CEA kinetics in predicting PD, and found that a circulating scoring system combining CEA kinetics, baseline CA19-9, and cfDNA values was independently associated with PD, PFS, and OS in mCRC patients.
BRITISH JOURNAL OF CANCER
(2021)